Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Aug 15, 2024 · CIK: 882361
Sentiment: neutral
Topics: 8-K, disclosure, financial-reporting
Related Tickers: APTO
TL;DR
APTO filed an 8-K, standard reporting stuff, no major news.
AI Summary
Aptose Biosciences Inc. filed an 8-K on August 15, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector. The filing does not contain specific financial figures or material events beyond the reporting of these items.
Why It Matters
This filing indicates Aptose Biosciences is fulfilling its reporting obligations with the SEC, which is standard procedure for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosure and exhibits, not indicating any new material events or financial changes.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- August 15, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 15, 2024.
What are the former names of Aptose Biosciences Inc. mentioned in the filing?
The former names of Aptose Biosciences Inc. mentioned are Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the Standard Industrial Classification code for Aptose Biosciences Inc.?
The Standard Industrial Classification code for Aptose Biosciences Inc. is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-08-15 16:35:12
Filing Documents
- f8k_081524.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-004831.txt ( ) — 221KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_081524_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 15, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: August 15, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer